Trimedat Forte, 300 mg 20 pcs.

Antispasmodic agent

ATC: A03AA05

Pharmacodynamics

Trimebutine acting on the encephalinergic system of the intestine is a regulator of its peristalsis. Acting on peripheral δ-, μ- and k receptors, including those located directly on the smooth muscles throughout the gastrointestinal tract (GIT), it regulates motility without affecting the central nervous system.

Indications

Symptomatic treatment of pain, cramps and discomfort in the abdomen, sensation of bloating (flatulence), intestinal motor disorders with changes in stool frequency (diarrhea or constipation), dyspepsia, heartburn, belching, nausea, vomiting associated with functional diseases of the gastrointestinal tract and biliary tract (non-erosive form of gastroesophageal reflux diseases; cholelithiasis; biliary tract dysfunction; irritable bowel syndrome; sphincter of Oddi dysfunction, postcholecystectomy syndrome).

Postoperative paralytic ileus.

Pharmacological effect

Antispasmodic

ATX: A03AA05

Pharmacodynamics

Trimebutine, acting on the enkephalinergic system of the intestine, is a regulator of its peristalsis. Acting on peripheral δ-, μ- and k receptors, including those located directly on smooth muscles throughout the gastrointestinal tract (GIT), it regulates motility without affecting the central nervous system.

Special instructions

To prevent relapse of irritable bowel syndrome after a course of treatment during the period of remission, it is recommended to continue taking the drug at a dose of 300 mg per day for 12 weeks.

Active ingredient

Trimebutine

Composition

One tablet contains:

active ingredient: trimebutine maleate – 300 mg;

excipients:

microcrystalline cellulose,

povidone (K 25),

hypromellose,

magnesium stearate;

shell composition: Opadray II 85F18422: partially hydrolyzed polyvinyl alcohol, macrogol-3350, titanium dioxide E 171, talc.

Pregnancy

Experimental studies have not revealed any evidence of teratogenicity or embryotoxicity of the drug. However, due to the lack of necessary clinical data, the use of Trimedat® forte during pregnancy is contraindicated.

It is not recommended to prescribe Trimedat® forte during lactation due to the lack of reliable clinical data confirming the safety of the drug during this period. If it is necessary to use the drug during lactation, breastfeeding should be stopped.

Contraindications

Hypersensitivity to the components included in the drug.

Pregnancy.

Children up to 12 years of age (for this dosage form).

Side Effects

From the digestive system: dry mouth, unpleasant taste, diarrhea, dyspepsia, nausea, constipation.

From the nervous system: drowsiness, fatigue, dizziness, headache, anxiety.

Allergic reactions: skin rash.

Other: menstrual irregularities, painful enlargement of the mammary glands, urinary retention.

Interaction

Drug interactions with Trimedat® forte have not been described.

Overdose

There have been no cases of overdose of Trimedat® forte reported to date.

Treatment: discontinuation of the drug, gastric lavage, administration of activated charcoal, symptomatic therapy. There are no specific antidotes.

Storage conditions

In original packaging at a temperature not exceeding 25 °C.

Keep out of the reach of children.

Shelf life

2 years.
Do not use after the expiration date stated on the package.

Manufacturer

Valenta Pharm JSC, Russia